Is LDL-C passed its prime?: The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 9, 2008, Pages 1582-1583

  Davidson, Michael H ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CONJUGATED ESTROGEN; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN PARTICLE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TARGETING; DYSLIPIDEMIA; EDITORIAL; ESTROGEN THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; BLOOD; CORONARY ARTERY DISEASE; FEMALE; NOTE; PATIENT SELECTION;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; PATIENT SELECTION; RISK ASSESSMENT;

EID: 51649092349     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.172718     Document Type: Editorial

References (12)

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak. RC, Smith SC. Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vase Biol. 2004;24:el49-el61.
2. Maki KC, Galant R, Davidson MH. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am. J Cardiol. 2005;96(9A): 59K-64K; discussion 34K-35K.
3. www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-10.pdf.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
5. Sniderman. AD, St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91:1173-1177.
6. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation, to cardiovascular events with statin treatment. Circulation. 2008;117:3002-3009.
7. Brunzell JD, Davidson. M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum. JL; American Diabetes Association; American College of Cardiology Foundation. Lipoprotein, management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31: 811-822.
8. Hsia J, Otvos JD, Rossouw JE, Wu L, Wassertheil-Smoller S, Hendrix SL, Robinson JG, Lund B, Kuller luteinizing hormone (LH); for the Women's Health Initiative Research Group. Lipoprotein particle concentrations may explain, the absence of coronary protection in the Women's Health Initiative Hormone Trials. Arterioscler Thromb Vasc Biol. 2008;28:1666-1671.
9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
10. Barter PJ, Caulfield M, Eriksson. M, Grundy SM, Kastelein. JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
11. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781.
12. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein, cholesterol: and the winner is. Circulation. 2005;112:3366-3367.